Vulvovaginitis in Emergency Medicine

Back

Background

Vulvovaginitis is common, affecting women of all ages. Vulvovaginitis is an inflammation of the vagina and vulva, most often caused by a bacterial, fungal, or parasitic infection. Vulvovaginitis, one of the most common reasons why women visit their gynecologist, causes vaginal discharge, irritation, and itching. Normally, a woman may have a vaginal discharge, the amount and consistency of which varies during the course of the menstrual cycle; however, vulvovaginitis causes a symptomatic increased vaginal discharge. Other symptoms associated with this condition are dyspareunia, dysuria, and odor.

Women with vulvovaginitis tend to be embarrassed or are worried about sexually transmitted diseases (STD). Self-treatment is usually the norm and close to 50% ineffective.[1] In this country alone, millions of dollars are wasted on over-the-counter antifungals because of self-treatment for candidiasis.[2] Providers may also be uncomfortable or do not have adequate time to diagnose the true etiology and may treat the wrong condition. Thus, vulvovaginitis is probably underdiagnosed.

Etiologies and the approach of management for a patient with vulvovaginitis are age dependent. Vulvovaginitis can be divided into 3 age categories: premenarchal, childbearing, and postmenopausal.

Pathophysiology

The normal vaginal epithelium cornifies (develops into a thickened layer of epithelial cells) under the influence of estrogen, protecting women against infection. A normal vaginal discharge consists of 1-4 mL of fluid that is white or transparent, thick, and odorless. This physiologic discharge is formed by sloughing epithelial cells, normal bacteria, and vaginal transudate. The discharge may be noticeable during pregnancy, oral contraceptive pill use, or at mid menstrual cycle, close to the time of ovulation.

The normal pH of vaginal secretions is 4.0-4.5.[3] The pH is maintained by lactobacillus, which produces hydrogen peroxide and lactic acid; diphtheroids; and Staphylococcus epidermidis.[2] Lactobacillus is found in 62-88% of women.[3] Vaginal pH may increase with age, phase of menstrual cycle, sexual activity, contraception choice, pregnancy, presence of necrotic tissue or foreign bodies, and use of hygienic products or antibiotics.[3]

Bacterial vaginosis is secondary to bacterial overgrowth and not due to tissue inflammation. The organisms associated with bacterial vaginosis are Gardnerella vaginalis, Mycoplasma hominis, and Mobiluncus, a facultative anaerobe.[4, 5] Summarizing, practically any condition changing the vaginal milieu may result in vulvovaginitis.

Epidemiology

Frequency

United States

Premenarchal

Vulvovaginitis is the most common gynecologic problem affecting prepubertal girls and is responsible for the largest number of visits to the gynecologist.

Childbearing age

Bacterial vaginosis is the most important cause of vulvovaginitis. Estimating the number of patients presenting with bacterial vaginosis is difficult because G vaginalis can be recovered from the vagina in 30-50% of asymptomatic women.[6]

Trichomonas vaginalis affects 2-3 million women annually in the United States. The organism also is detected in 30-40% of men who are exposed to women with T vaginalis.[3] The prevalence of T vaginalis infection at clinics treating sexually transmitted diseases (STDs) varies from 8-31%. In men, T vaginalis may account for as many as 17% of cases of nongonococcal, nonchlamydial urethritis. T vaginalis infection appears to be more common in the southern United States.

Candidal vulvovaginitis is considered slightly less common than bacterial vaginosis, yet, 3 out of every 4 women in the United States will have at least 1 bout of vulvovaginal candidiasis (VVC) during their lifetime.[4, 6] Patients with recurrent or severe vulvovaginal candidiasis warrant a screening test for diabetes mellitus.

Postmenopausal

After menopause, most women experience some vaginal atrophy as estrogen levels fall. Incidence of atrophic vaginitis depends on how it is defined. Vulvovaginitis related to infection is much less common after menopause. Desquamative inflammatory vaginitis, an exception, has an unknown etiology, but a Gram stain of culture often reveals streptococci. This is treated with intravaginal clindamycin cream or a topical or intravaginal steroid.[7] Postirritation vulvovaginitis may occur in women undergoing pelvic irradiation for cancer.

International

Bacterial vaginosis is the most common cause of vaginitis in women of childbearing age, with prevalence of 50-60% across the globe.

Trichomoniasis affects 180 million women worldwide.

Mortality/Morbidity

No mortality has been documented primarily from vulvovaginitis.

Race

Sex

Vulvovaginitis does not occur in males. Males may be carriers of G vaginalis and T vaginalis.

Age

History

Different historical aspects should be ascertained depending on what vulvovaginitis category the patient may have.

Physical

Causes

Laboratory Studies

Prehospital Care

Emergency Department Care

Consultations

Medication Summary

Treatment should be aimed at bacterial, parasitic, or fungal infection.

Metronidazole (Metro-Gel, Noritate)

Clinical Context:  Imidazole ring-based antibiotic active against various anaerobic bacteria and protozoa. Indicated for treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, anaerobic vaginosis).

Penicillin VK (Veetids, Beepen-VK)

Clinical Context:  Indicated when the offending organism is group A streptococci. Inhibits biosynthesis of cell wall mucopeptide and is effective during active replication. Inadequate concentrations may produce only bacteriostatic effects.

Tinidazole (Tindamax)

Clinical Context:  5-Nitroimidazole derivative used for susceptible protozoal infections. The mechanism by which tinidazole exhibits activity against Giardia and Entamoeba species is not known.

Erythromycin (EES, E-Mycin, Ery-Tab)

Clinical Context:  DOC for penicillin-allergic patients with infections caused by susceptible strains of microorganisms, including group A streptococci. Inhibits RNA-dependent protein synthesis, possibly by stimulating dissociation of peptidyl tRNA from ribosomes, which inhibits bacterial growth.

In children, age, weight, and severity of infection determine proper dosage. When bid dosing is desired, half-total daily dose may be taken q12h. For more severe infections, double the dose.

Clindamycin (C/T/S, Clinda-Derm, Cleocin HCl)

Clinical Context:  Useful as treatment against serious skin and soft tissue infections caused by most staphylococcal strains. Inhibits bacterial protein synthesis by inhibiting peptide chain initiation at the bacterial ribosome, where it preferentially binds to the 50S ribosomal subunit, causing bacterial growth inhibition. Has a 90% cure rate and is used as an alternative to metronidazole.

Class Summary

Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the clinical setting.[25]

A 7-day oral course yields a 90% cure, and single oral dose therapy yields an 80% cure. Relapses are common requiring a longer duration of treatment.[26] Combinations of antibiotics have no benefit.[25, 26] If single oral dose therapy is ineffective, either administer a second oral dose in 48 hours or initiate weeklong therapy. Some patients prefer intravaginal medication.[10] Treatment of bacterial vaginosis before 20 weeks' gestation may decrease preterm delivery.[27] Only those women who are symptomatic from bacterial vaginosis should be screened.[10, 28, 5] Topical metronidazole gel poorly achieves therapeutic concentration in the urethra and Skene's gland and therefore is not indicated in Trichomonas infections.[19] Tinidazole may have less side effects than metronidazole and can be used in the rare case of metronidazole resistance.[29]

Hydrocortisone topical (Cortef Feminine Itch, Delcort)

Clinical Context:  DOC because of its mineralocorticoid activity and glucocorticoid effects.

Primary therapeutic effects of topical corticosteroids are from their anti-inflammatory activity, which is nonspecific (ie, they act against most causes of inflammation including mechanical, chemical, microbiological, immunological).

Do not use very high or high-potency agents on the face, groin, or axilla.

Class Summary

These agents are used to treat extreme vaginal pruritus. Cream is for symptomatic relief, especially in pediatric vulvovaginitis.

These agents are adrenocorticosteroid derivatives incorporated into a vehicle suitable for application to skin or external mucous membranes.

Butoconazole (Femstat)

Clinical Context:  Broad-spectrum antifungal agent that inhibit yeast growth by altering cell membrane permeability, which causes fungal cell death.

Tioconazole (Vagistat)

Clinical Context:  Broad-spectrum antifungal agent that inhibit yeast growth by altering cell membrane permeability, which causes fungal cell death.

Clotrimazole (Mycelex-7)

Clinical Context:  Broad-spectrum antifungal agents that inhibit yeast growth by altering cell membrane permeability, which causes fungal cell death.

Fluconazole (Diflucan)

Clinical Context:  Synthetic oral antifungal (broad-spectrum bistriazole) that selectively inhibits fungal cytochrome P-450 and sterol C-14 alpha-demethylation. Consider ease of use, although direct cost may be a limiting factor. Do not recommend PO antifungals in pregnancy.

Miconazole vaginal (Monistat Vaginal)

Clinical Context:  Broad-spectrum antifungal agent that inhibit yeast growth by altering cell membrane permeability, which causes fungal cell death.

Terconazole (Terazol 3, Terazol 7)

Clinical Context:  Broad-spectrum antifungal agent that inhibit yeast growth by altering cell membrane permeability, which causes fungal cell death.

Ketoconazole topical (Kuric 2%, Xolegel 2%)

Clinical Context:  Broad-spectrum antifungal agents that inhibit yeast growth by altering cell membrane permeability, which causes fungal cell death.

Nystatin

Clinical Context:  Broad-spectrum antifungal agent that inhibit yeast growth by altering cell membrane permeability, which causes fungal cell death.

Class Summary

These agents are used to treat candidal vulvovaginitis. Topical azole antifungals achieve cure rates of 85-95%. Nystatin demonstrates a 75-80% cure rate. Oral fluconazole has a cure rate comparable to topical azole antifungals.[30] It may be preferred by patients because of the ease of one-time dosing.

Intravaginal and topical therapies with a variety of antifungals, such as clotrimazole, miconazole, terconazole, and tioconazole, are highly effective. Many of the preparations are now available OTC. 1-, 3-, and 7-day regimens can be used. Cure rates of 90% are reported with longer courses.

Conjugated estrogens (Premarin)

Clinical Context:  Several topical steroid preparations are available, including equine estrogen, estradiol, and dienestrol. Estrogens are indicated for atrophic vaginitis and atrophic urethritis associated with menopause.

Class Summary

These agents are used in treatment of atrophic vaginitis in postmenopausal women. Oral estrogen replacement also is effective and has other health benefits. Oral estrogen therapy generally should be initiated by a primary care provider rather than an ED clinician.

Mebendazole (Vermox)

Clinical Context:  Indicated drug to treat pinworm. Kills worms by selectively and irreversibly blocking glucose uptake and other nutrients in the susceptible adult intestine where helminths dwell.

Pyrantel pamoate (Pin-Rid, Pin-X, Reese Pinworm)

Clinical Context:  Used as an alternative to mebendazole; a depolarizing neuromuscular blocking agent that inhibits cholinesterases, resulting in spastic paralysis of the worm. Active against E vermicularis (ie, pinworm) and Ascaris lumbricoides (ie, roundworm). Also effective against Ancylostoma duodenale (ie, hookworm). Purging is not necessary; may be taken with milk or fruit juices.

Class Summary

These agents are used to treat parasitic infections. Parasite biochemical pathways are sufficiently different from the human host to allow selective interference by chemotherapeutic agents in relatively small doses.

Tamoxifen (Nolvadex)

Clinical Context:  May be used for women who are very concerned about estrogen exposure. Known to have both estrogen antagonist and agonist effects, depending on target tissue.

Class Summary

These agents competitively bind to estrogen receptor, producing a nuclear complex that decreases DNA synthesis and inhibits estrogen effects.

Further Outpatient Care

Deterrence/Prevention

Complications

Prognosis

Author

Mark J Leber, MD, MPH, FACEP, Attending Physician and Faculty, Department of Emergency Medicine and Residency Program, Lincoln Medical and Mental Health Center

Disclosure: Nothing to disclose.

Coauthor(s)

Anuritha Tirumani, MD, Research Coordinator, Department of Emergency Medicine, Brooklyn Hospital Center

Disclosure: Nothing to disclose.

Specialty Editors

David S Howes, MD, Professor of Medicine and Pediatrics, Section Chief and Emergency Medicine Residency Program Director, University of Chicago Division of the Biological Sciences, The Pritzker School of Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Mark Zwanger, MD, MBA, Assistant Professor, Department of Emergency Medicine, Jefferson Medical College of Thomas Jefferson University

Disclosure: Nothing to disclose.

John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center

Disclosure: Nothing to disclose.

Chief Editor

Pamela L Dyne, MD, Professor of Clinical Medicine/Emergency Medicine, University of California, Los Angeles, David Geffen School of Medicine; Attending Physician, Department of Emergency Medicine, Olive View-UCLA Medical Center

Disclosure: Nothing to disclose.

Acknowledgments

The authors and editors of eMedicine gratefully acknowledge the contributions of previous author, Reza Keshavarz, MD, to the development and writing of this article.

References

  1. B Angotti L, C Lambert L, E Soper D. Vaginitis: making sense of over-the-counter treatment options. Infect Dis Obstet Gynecol. 2007;2007:97424. [View Abstract]
  2. Nyirjesy P. Vulvovaginal candidiasis and bacterial vaginosis. Infect Dis Clin North Am. Dec 2008;22(4):637-52, vi. [View Abstract]
  3. Katz. Vaginitis. In: Mosby. Katz:Comprehensive Gynecology. 5th ed. Elsevier; 2007:588-596.
  4. Szumigala JA, Alveredo R. Vulvovaginitis. In: Mosby. Ferri: Ferri's Clinical Advisor 2009. ed. Elsevier; 2009:155,1008-1012.
  5. [Guideline] Workowski KA, Berman SM. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines 2006. 2009;
  6. Eckert LO. Clinical practice. Acute vulvovaginitis. N Engl J Med. Sep 21 2006;355(12):1244-52. [View Abstract]
  7. Margesson LJ. Vulvar disease pearls. Dermatol Clin. Apr 2006;24(2):145-55, v. [View Abstract]
  8. Braverman Paula k. Urethritis, Vulvovaginitis, and Cervicitis. In: Churchill Livingstone. Principals and Practice of Pediatric Infectious Diseases. 3rd ed. Elsevier; 2008:55.
  9. Farage MA, Miller KW, Ledger WJ. Determining the cause of vulvovaginal symptoms. Obstet Gynecol Surv. Jul 2008;63(7):445-64. [View Abstract]
  10. Biggs WS, Williams RM. Common gynecologic infections. Prim Care. Mar 2009;36(1):33-51, viii. [View Abstract]
  11. Hampton T. High prevalence of lesser-known STDs. JAMA. Jun 7 2006;295(21):2467. [View Abstract]
  12. Helms DJ, Mosure DJ, Metcalf CA, Douglas JM Jr, Malotte CK, Paul SM, et al. Risk factors for prevalent and incident Trichomonas vaginalis among women attending three sexually transmitted disease clinics. Sex Transm Dis. May 2008;35(5):484-8. [View Abstract]
  13. Jasper J. Vulvovaginitis in the prepubertal child. Clin Pediatr Emerg Med. Mar 2009;10.
  14. Freeto JP, Jay MS. "What's really going on down there?" A practical approach to the adolescent who has gynecologic complaints. Pediatr Clin North Am. Jun 2006;53(3):529-45, viii. [View Abstract]
  15. Johnson E, Berwald N. Evidence-based emergency medicine/rational clinical examination abstract. Diagnostic utility of physical examination, history, and laboratory evaluation in emergency department patients with vaginal complaints. Ann Emerg Med. Sep 2008;52(3):294-7. [View Abstract]
  16. Ferris DG, Francis SL, Dickman ED, Miler-Miles K, Waller JL, McClendon N. Variability of vaginal pH determination by patients and clinicians. J Am Board Fam Med. Jul-Aug 2006;19(4):368-73. [View Abstract]
  17. Kulp JL, Chaudhry S, Wiita B, Bachmann G. The accuracy of women performing vaginal pH self-testing. J Womens Health (Larchmt). May 2008;17(4):523-6. [View Abstract]
  18. Chatwani AJ, Mehta R, Hassan S, Rahimi S, Jeronis S, Dandolu V. Rapid testing for vaginal yeast detection: a prospective study. Am J Obstet Gynecol. Apr 2007;196(4):309.e1-4. [View Abstract]
  19. Hollier LM, Workowski K. Treatment of sexually transmitted infections in women. Infect Dis Clin North Am. Dec 2008;22(4):665-91, vi. [View Abstract]
  20. Pillay A, Radebe F, Fehler G, Htun Y, Ballard RC. Comparison of a TaqMan-based real-time polymerase chain reaction with conventional tests for the detection of Trichomonas vaginalis. Sex Transm Infect. Apr 2007;83(2):126-9. [View Abstract]
  21. Schwiertz A, Taras D, Rusch K, Rusch V. Throwing the dice for the diagnosis of vaginal complaints?. Ann Clin Microbiol Antimicrob. Feb 17 2006;5:4. [View Abstract]
  22. Heller DS, Maslyak S, Skurnick J. Is the presence of Trichomonas on a Pap smear associated with an increased incidence of bacterial vaginosis?. J Low Genit Tract Dis. Jul 2006;10(3):137-9. [View Abstract]
  23. [Guideline] Huntzinger A. Practice Guideline Briefs. American Family Physician. Nov 2006;74.
  24. Mania-Pramanik J, Kerkar SC, Mehta PB, Potdar S, Salvi VS. Use of vaginal pH in diagnosis of infections and its association with reproductive manifestations. J Clin Lab Anal. 2008;22(5):375-9. [View Abstract]
  25. Schwebke JR, Desmond R. A randomized trial of metronidazole in asymptomatic bacterial vaginosis to prevent the acquisition of sexually transmitted diseases. Am J Obstet Gynecol. Jun 2007;196(6):517.e1-6. [View Abstract]
  26. Schwebke JR, Desmond RA. A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis. Clin Infect Dis. Jan 15 2007;44(2):213-9. [View Abstract]
  27. Swadpanich U, Lumbiganon P, Prasertcharoensook W, Laopaiboon M. Antenatal lower genital tract infection screening and treatment programs for preventing preterm delivery. Cochrane Database Syst Rev. Apr 16 2008;CD006178. [View Abstract]
  28. Carey JC, Klebanoff MA, Hauth JC, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. Feb 24 2000;342(8):534-40. [View Abstract]
  29. Nailor MD, Sobel JD. Tinidazole for the treatment of vaginal infections. Expert Opin Investig Drugs. May 2007;16(5):743-51. [View Abstract]
  30. Marrazzo J. Vulvovaginal candidiasis. BMJ. Sep 14 2002;325(7363):586. [View Abstract]
  31. Mann JR, McDermott S, Zhou L, Barnes TL, Hardin J. Treatment of trichomoniasis in pregnancy and preterm birth: an observational study. J Womens Health (Larchmt). Apr 2009;18(4):493-7. [View Abstract]
  32. [Best Evidence] Buckling J. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst. Rev. 2006;4:[View Abstract]
  33. Donders G, Bellen G, Byttebier G, Verguts L, Hinoul P, Walckiers R, et al. Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial). Am J Obstet Gynecol. Dec 2008;199(6):613.e1-9. [View Abstract]
  34. Van Der Pol B, Kwok C, Pierre-Louis B, Rinaldi A, Salata RA, Chen PL, et al. Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women. J Infect Dis. Feb 15 2008;197(4):548-54. [View Abstract]
  35. Gabbe SG. Vaginal infections. In: Obstetrics - Normal and Problem Pregnancies. 4th ed. 2002.
  36. Johns Hopkins. Diagnostic features and management of vaginal infections. In: The Harriet Lane Handbook: A Manual for Pediatric House Officers. 17th ed. 2005.
  37. Owen MK, Clenney TL. Management of vaginitis. Am Fam Physician. Dec 1 2004;70(11):2125-32. [View Abstract]
  38. Sobel JD. Vaginitis, vulvitis, cervicitis and cutaneous vulval lesions. In: Infectious Diseases. 2nd ed. Cohen & Powderly; 2004.

The photomicrograph reveals bacteria adhering to vaginal epithelial cells known as clue cells. The presence of clue cells is a sign that the patient has bacterial vaginosis. Source CDC Phil/ M.Rein.

Candida albicans photomicrograph. Source CDC.

The photomicrograph reveals bacteria adhering to vaginal epithelial cells known as clue cells. The presence of clue cells is a sign that the patient has bacterial vaginosis. Source CDC Phil/ M.Rein.

Candida albicans photomicrograph. Source CDC.

empty para to satisfy content model